1. Guidance for Industry on Diabetes Mellitus-Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. A Notice by the Food and Drug Administration on 12/19/2008,2021
2. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes;Zinman;N Engl J Med,2015
3. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes;Neal;N Engl J Med,2017
4. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes;Wiviott;N Engl J Med,2019
5. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes;Cannon;N Engl J Med,2020